Clinical Trial Update: HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating conversion therapy with hepatic arterial infusion chemotherapy (HAIC), lenvatinib, and cadonilimab for initially unresectable hepatocel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Cadonilimab
• LENVIMA (lenvatinib)

Snippet

Sponsor: Tongji Hospital | Conditions: Hepatocellular Carcinoma Non-resectable | Phase 2 | Status: ACTIVE_NOT_RECRUITING